KANCERA IS DEVELOPING A NEW GENERATION OF DRUGS AGINST CANCER AND INFLAMMATION
Kancera develops the basis for new therapeutics, starting with new treatment concepts and ending with the sale of a drug candidate to international pharmaceutical companies. Kancera is currently developing drugs for the treatment of inflammation and cancer, by regulating the immune system, blocking survival signals in the cancer cell and addressing repair mechanisms.
Kancera was founded in the spring of 2010. On February 25, 2011, the share was listed on NASDAQ OMX First North.